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Compulsory patent licensing and local drug manufacturing capacity  
in Africa
Olasupo Ayodeji Owoeyea
International patent law and access to 
medicines
Since the adoption of the Agreement on Trade-Related As-
pects of Intellectual Property Rights (hereafter, the “TRIPS 
Agreement”) in 1994, the implications of the World Trade 
Organization (WTO) intellectual property regime for access 
to medicines in developing countries have been the subject of 
robust discussion. By imposing certain minimum standards of 
intellectual property protection for all WTO member states, 
the TRIPS Agreement made it mandatory for such states to 
recognize patents for pharmaceutical products to the extent that 
the products meet the criteria for patentability. Owing to these 
standards, countries such as China and India, which have built 
strong manufacturing capacity in the pharmaceutical sector, 
might no longer be able to produce generic versions of patented 
drugs.1 This restriction will substantially undermine the supply 
of drugs to African countries: in 2011 China and India alone 
accounted for over 20% of pharmaceutical imports into Africa.2
A practical way of preventing the abuse of patent rights 
under the TRIPS Agreement is compulsory licensing, which 
allows governments to authorize the use of patented products 
without the consent of the holder of the patent right.3 Such 
authority may be granted to an agent of the government or to 
an independent third party. Compulsory patent licences may 
be issued to meet the demand for a patented product in a do-
mestic market, to enhance competition by aiding the growth 
of domestic competitors, or to facilitate the development or 
establishment of a domestic market.3 Compulsory licensing 
may also be used to protect the public interest, especially dur-
ing public health emergencies, or to act as a safeguard against 
abuses that might arise from the monopoly rights conferred 
by patents.4
Article 31(f) of the TRIPS Agreement provides that prod-
ucts made under a compulsory licence shall be predominantly 
for use in the domestic market of the country granting the 
licence. Because this provision does little to increase access 
to medicines in countries with little or no pharmaceutical 
manufacturing capacity, paragraph 6 of the Doha Declaration 
on the TRIPS Agreement and Public Health mandated that 
the TRIPS Council help such countries meet their pharma-
ceutical needs.5 Some of the measures taken by the WTO are 
specified in Table 1.
African disease burden and TRIPS
Africa bears a very heavy burden of disease. According to the 
World Health Organization (WHO), 61.2% of deaths in the 
WHO African Region during 2011 were caused by communi-
cable diseases, maternal and neonatal diseases and nutritional 
deficiencies that in many instances can be treated successfully 
with pharmaceutical agents.10 WTO law currently contains 
considerable flexibilities that facilitate access to affordable 
medicines. For instance, of the world’s least developed coun-
tries, 26 of those that are WTO members have allowed the 
importation of generic health products, irrespective of their 
patent status, by adopting legislation that relies on provisions 
in the Doha Declaration.11 However, recent studies show that 
the median availability of generic medicines in the public sec-
tor in Africa – defined as the percentage of outlets that have a 
given generic medicine in stock – is only about 40%.12 In the 
private sector, the median availability of generic medicines and 
of originator brand products is less than 60% and less than 
25%, respectively.12 The median prices of the lowest-priced 
generic medicines in the African private sector are 6.7 times 
the international reference prices, whereas the median prices 
of originator brand medicines are as high as 20.5 times the 
international reference prices.12
Many off-patent drugs can be obtained as substitute 
medicines and it has been argued that patents might not 
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inhibit access in developing countries 
to essential pharmaceuticals on WHO’s 
Model Lists of Essential Medicines.13 
There are, however, circumstances in 
which patents might play a major role in 
hindering access. Compulsory licensing 
remains one of the most effective ways of 
ensuring access to drugs while prevent-
ing patents abuse, but there are limits 
to its effectiveness. Although African 
countries with little or no pharmaceuti-
cal manufacturing capacity can import 
generic versions of drugs from outside 
the continent, many new medicines 
might not be eligible for importation 
owing to the current global standard for 
intellectual property protection.
It seems unrealistic to expect 
these standards to become less restric-
tive, because the international patent 
system is flexible enough to enable 
countries to deliver responsible gov-
ernance and use the system to address 
their problems provided they have 
the political will to do so. The recent 
decision in Novartis AG v. Union of 
India (2013) lends credence to the 
argument that the TRIPS Agreement 
can still be implemented in a way con-
ducive to the socioeconomic welfare of 
countries.14 In this case, the Supreme 
Court of India held that the Novartis-
manufactured drug Glivec (which is 
already patented in Switzerland and 
the United States of America) was not 
patentable in India because it failed to 




Most African countries lack the neces-
sary pharmaceutical manufacturing 
capacity for effective use of compul-
sory licensing.15 Among sub-Saharan 
countries, only South Africa has a 
limited primary manufacturing ca-
pacity (i.e. it is capable of producing 
active pharmaceutical ingredients).16 
It is equally notable that the existing 
frameworks for compulsory licensing 
in several African countries are not 
fully compliant with the TRIPS Agree-
ment (Table 2). Exceptions include 
countries such as Ghana and Rwanda, 
which have fully incorporated into 
their national law the provisions of 
international conventions on intel-
lectual property law to which they are 
signatories. Multinational pharmaceu-
tical corporations have raised minimal 
objections to the lack of compliance 
with the TRIPS Agreement because 
the necessary infrastructure for ag-
gressive use of compulsory licenses 
does not exist in Africa. As recently as 
2008, 90% of the medicines available 
in sub-Saharan African countries were 
imported from outside Africa and 80% 
of the drugs used to treat human im-
munodeficiency virus (HIV) infection 
across the continent were imported.22
Foreign aid has played a signifi-
cant role in making drugs available in 
Africa, particularly those for treating 
HIV infection.16 The availability of these 
and other medicines might decrease 
substantially if the flow of capital and 
Table 1. Select World Trade Organization (WTO) measures taken in response to the 
TRIPS Agreementa
Measure Purpose
Least-Developed Country Members – 
Obligations Under Article 70.9 of the TRIPS 
Agreement with Respect To Pharmaceutical 
Products6
Allows least developed countries to refuse 
to maintain the standards imposed by TRIPS 
in respect of pharmaceutical products until 
1 January 2016 with an option for possible 
extension
Implementation of Paragraph 6 of the Doha 
Declaration on the TRIPS Agreement and 
Public Health7
Enables countries to produce and export 
medicines pursuant to a compulsory licence 
to countries that cannot produce them 
locally
Amendment of the TRIPS Agreement8 Incorporates provisions of the 
Implementation Decision as an amendment 
to the TRIPS Agreement; enters into force 
once accepted by two thirds of all WTO 
members
Extension of the Transition Period Under Article 
66.1 for Least Developed Country Members9
Extends the time for least developed 
countries to implement the minimum 
standard of intellectual property protection 
required by the TRIPS Agreement to 1 July 
2021
a  Agreement on Trade-Related Aspects of Intellectual Property Rights.
Table 2. Intellectual property laws in select sub-Saharan African countries and the 
degree of their compliance with the TRIPS Agreementa
Legislation, country Degree of compliance
Patent Act 2003 (Act 657), Ghana17 Gives supremacy to international treaties 
over domestic laws when there is conflict 
between them (fully compliant with the TRIPS 
Agreement)
Industrial Property Act 2001 (section 80), 
Kenya18
Allows compulsory licences to be granted 
without meeting the prior negotiation 
requirement or paying remuneration to 
the patent holder (inconsistent with TRIPS 
Agreement Article 31)
Patents and Designs Act 1990 (paragraph 15, 
schedule 1), Nigeria19
Same as that of the Kenyan legislation
Law No. 31/2009 of 26/10/2009 on the 
Protection of Intellectual Property 2009, 
Rwanda20
Same as that of the Ghanaian legislation
Medicines and Related Substances 
Amendment Act 2002 (section 15C[a]), South 
Africa21
Provides that patent rights on a medicine 
may not extend to any medicine that has 
been put onto the market by the owner or 
with the owner’s consent; obviates the need 
for a compulsory licence in respect of any 
medicine that has been put on the market 
anywhere in the world by the owner or 
with their consent (inconsistent with TRIPS 
Agreement Articles 28 and 31)
a  Agreement on Trade-Related Aspects of Intellectual Property Rights.
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aid to developing countries continues 
to dwindle23 and a self-reliant means of 
ensuring medicine availability remains 
absent. The time has therefore come for 
Africa to look beyond foreign aid to 
increase its access to medicines.
The African Union has begun in-
vestigating strategies for the full use of 
compulsory licensing on the continent. 
In the 2005 Gaborone Declaration, 55 
African ministers of health agreed to 
find ways to take advantage of the flex-
ibilities offered by the TRIPS Agreement 
and the Doha Declaration.24 A draft 
pharmaceutical manufacturing plan 
was created in 2007 and it was recom-
mended that a technical committee be 
established to produce a detailed report 
on the implications of local production 
of pharmaceuticals in Africa.25 In its 
subsequent report, the technical com-
mittee asserted that the local production 
of affordable, high-quality, safe and 
efficacious medicines is possible only 
if African countries work together to 
strengthen drug manufacturing capac-
ity.22 The 2012 business plan for Africa’s 
pharmaceutical manufacturing plan 
emphasized the need for collaboration 
among stakeholders at the national and 
international community levels to en-
able sustainable progress in developing 
substantial pharmaceutical manufactur-
ing capacity on the continent, as well 
as the importance of establishing an 
effective legal basis for collaboration.22 
The African Union’s position seems to 
place more emphasis on national and 
regional collaborative efforts.16 However, 
continent-wide collaboration overseen 
by the African Union and involving rep-
resentatives from each region in Africa 
is likely to be a more effective means of 
creating local manufacturing capacity.
Economic collaboration
To obtain high-priced medicines, espe-
cially if they are patented, a recent study 
undertaken under the auspices of the 
WHO recommended the application of 
political pressure to achieve differential 
pricing and the use of legal flexibilities 
available under the TRIPS Agreement.12 
The use of political pressure can be 
greatly enhanced through the forma-
tion of an African free trade area. As 
part of its mandate, the TRIPS Council 
stipulated that if a developing or least 
developed WTO member country is 
part of a regional trade agreement (RTA) 
within the context of the WTO, goods 
produced in or imported under a com-
pulsory licence to that country can be 
exported to other developing countries 
or to least developed member countries 
in the RTA that share the health prob-
lem the goods are intended to alleviate, 
provided that half of the parties to the 
RTA are recognized as least developed 
countries by the United Nations.7,8 This 
provision allows developing countries 
to aggregate their markets to make the 
creation of a local pharmaceutical in-
dustry more attractive.26 More than half 
of the countries in Africa are currently 
recognized by the United Nations as 
least developed countries. An African 
RTA will therefore make it possible 
under WTO law to issue compulsory 
licences for the importation of drugs 
that can circulate without trade or legal 
barriers within the continent. An Afri-
can free trade zone will also provide a 
substantial, commercially viable market 
and will thus dissolve a major concern, 
raised in a recent evidence-based study, 
about whether local production would 
yield a large commercial market oppor-
tunity.27 There is therefore a compelling 
need to build a regional alliance not only 
to build strong pharmaceutical manu-
facturing capacity, but also to facilitate 
trade within the African region.
The case for an African 
regional trade agreement
The Treaty Establishing the African 
Economic Community (hereafter, the 
“African Treaty”) was signed on 3 June 
1991 by 51 African heads of state and 
government. Article 6 of the African 
Treaty provides that the community 
shall be established over a transitional 
period not exceeding 34 years, with an 
allowance of up to 40 years for the cu-
mulative transitional period. However, 
during the 22 years since the adoption 
of the African Treaty not much has 
been done towards the establishment 
of the community. The current public 
health crisis in Africa has made exigent 
the need to facilitate the full realization 
of the African Treaty’s objectives. Such 
an economic alliance will give Africa a 
stronger voice in international politics, 
better economic leverage in interna-
tional trade and the ability to harness 
the resources of WTO member states 
to substantially advance socioeconomic 
development in the continent. Substan-
tial manufacturing capacity can thus be 
built in Africa by using the platform 
of an African RTA to harness existing 
resources and establish an industry that 
is owned jointly by the community and 
managed by an umbrella body, such as 
the African Union. Although the im-
mediate establishment of an African 
economic community might not nec-
essarily attract popular support at the 
moment, steps can be taken to unify 
the existing eight regional economic 
communities on the African continent 
to establish an African free trade area as 
soon as possible.
Africa has been recording some 
economic growth in recent years.28 
The argument that the continent is too 
poor to have a strong pharmaceutical 
manufacturing capacity may therefore 
not be supportable in the light of cur-
rent developments. According to the 
International Monetary Fund’s world 
economic outlook for 2012, Africa is 
recording strong economic growth com-
pared with other parts of the world.29 
The African Union can use the platform 
of an economic coalition through the 
instrumentality of an RTA to take advan-
tage of the current growth in the African 
economy and bring African countries 
together to build a strong manufacturing 
capacity in the pharmaceutical sector. 
This will surely go a long way towards 
improving health-care delivery in Africa 
and bringing about the much desired 
growth in human development on the 
continent. Besides, the development 
of significant manufacturing capacity 
in the pharmaceutical sector, coupled 
with the transitional provisions in the 
TRIPS Agreement that enable the least 
developed countries to derogate from 
obligations under the agreement until 
2021, will enable Africa to take full 
advantage of compulsory licensing and 
generic manufacturing on the continent, 
pending the expiration of the transi-
tional arrangement.
The formation of an African RTA 
at this stage will not only facilitate the 
eventual establishment of an African 
economic community but can also en-
able the continent to obtain compulsory 
licences from patent pools to meet its 
public health demands. A patent pool 
is constituted when two or more patent 
owners put their patents together in such 
a way that authorization for use can be 
granted for all patents in the pool as a 
single package.30 Through a regional 
collaborative arrangement, African 
countries can obtain licences from the 
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pool to meet the health needs of their 
populations, especially in relation to 
the epidemic of HIV infection. Because 
the TRIPS Agreement requires parties 
to seek voluntary licences before they 
resort to seeking compulsory licensing, 
an African RTA can also provide a stron-
ger platform for negotiating the terms of 
voluntary licences. When a voluntary 
licence cannot be obtained, an African 
RTA can enable a single African country 
to issue a compulsory licence for local 
production or importation to meet its 
internal needs and the needs of other 
countries that are parties to the RTA.7
Conclusion
Although the problem of poor access 
to medicines in Africa did not begin 
with the adoption of the TRIPS Agree-
ment, the agreement has exacerbated it. 
Continued reliance on foreign aid will 
not resolve the problem. As emerging 
economies in Asia begin to implement a 
more protectionist intellectual property 
framework, Africa is ill-advised to con-
tinue relying on generic manufacturers 
in Asia for access to affordable pharma-
ceuticals. There is therefore an urgent 
need for Africa to begin developing a 
strong pharmaceutical manufacturing 
capacity. Although it might be particu-
larly difficult for a single African country 
to do this, countries can pool resources 
through an economic coalition in the 
form of an African RTA to develop 
a capacity strong enough to provide 
medicines for the continent.
The benefits Africa stands to gain 
from developing strong manufacturing 
capacity in the pharmaceutical sector are 
immense: of the 54 fully recognized sov-
ereign states in Africa, 33 are ranked as 
least developed countries by the United 
Nations31 and are therefore eligible to re-
fuse to grant patents for pharmaceuticals 
until July 2021. Thus, building a strong 
manufacturing capacity on the conti-
nent at this stage not only will facilitate 
the production of generic drugs in the 
continent but also will make the effec-
tive use of compulsory licences much 
easier and attractive. Local production 
of pharmaceuticals, coupled with the 
formation of an African free trade area, 
will facilitate the movement of drugs 
within the continent, without trade bar-
riers or excise duties, inexorably leading 
to cheaper drugs throughout Africa. It 
will also spur human development and 
improve the technological base of the 
continent. Until Africa develops local 
manufacturing capacity and substan-
tially reduces the current barriers to 
free trade on the continent, the effective 
use of compulsory licences is likely to 
remain a highly daunting task. ■
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صخلم
ايقيرفأ في ةيلحلما ةيودلأا عينصت ةردقو عاترخلاا تاءابرل يمازللإا صيخترلا
 دماتعلاا في رمتستو لماعلا في ضارمأ ءبع بركأ تتح ايقيرفأ حزرت
 ةحصلا  تاجايتحا  ةيبلتل  ةينلاديصلا  تاضرحتسلما  تادراو  لىع
 ايسآ  في  ةسينلجا  ةيودلأا  عينصت  تاكشر  ءدبل  ًارظنو  .ةيمومعلا
 نإف  ،ةيماحلل  ًماعد  رثكأ  ةيركفلا  ةيكلملل  ماظن  لظ  في  لمعلا  في
 حبصت  رقفلأا  نادلبلل  ةلوقعم  راعسأب  ةيودلأا  عينصت  لىع  اتهردق
 ةحصلاو سبيرت قافتا  نأشب ةحودلا نلاعإ حنميو .ًادج ةدودمح
 رارقإ في قلحا ةيلماعلا  ةحصلا ةمظنم في ءاضعلأا لودلا ةيمومعلا
 عاترخلاا  تاءارب  لىع  ةلصالحا  داولما  مادختساب  حمست  تاعيشرت
 فورعلما  طشرلا  وهو  ،عاترخلاا  ةءارب  لماح  نم  صيخرت  نود
 نم يتلا  ةيقيرفلأا نادلبلل  ةبسنلابو .“يمازللإا صيخترلا”  مساب
 بيج هنإف  ،يمازللإا  صيخترلا  نم لماك لكشب ديفتست  نأ  ررقلما
 عينصتلا ةردق ءانب نلأ ًارظنو .ةيساسأ ةيلمح عينصت ةردق روطت نأ
 ءاشنإ  يغبني  ،ًابيرقت  يعقاو  يرغو  لئاه  رمأ  يقيرفأ  دلب  لك  في
 نم  طقف  سيل  ،ةدعاقك  اهمادختسلا  ةيقيرفأ  ةرح  ةراتج  ةقطنم
 نكلو  ،ةيمازللإا  صيخاترلاب  بجومب  عئاضبلا  ةكرح  ةيرح  لجأ
 عينصت ةردق ريوطت بوص ليام وأ يداصتقا نواعت لجأ نم ًاضيأ
 في نادلبلا مظعم عقتو .ةراقلا في ةينلاديصلا تاضرحتسملل ةيوق
 حيتي  اذهو  ًاومن  نادلبلا  لقلأ  ةدحتلما  مملأا  ةمئاق  نمض  ايقيرفأ
 تاءارب  حنم  ضفر  ،ةيلماعلا  ةراجتلا  ةمظنم  نوناق  بجومب  ،اله
 ،مث نمو .2021  ماع ىتح ةينلاديصلا تاضرحتسملل عاترخلاا
 ةردق ءانبل نواعتلاب ةيقيرفلأا نادلبلا موقت نلأ ةحلم ةجاح دجوت
 ينح  في  ،نلآا  ةراقلا  في  ةينلاديصلا  تاضرحتسملل  ةيوق  عينصت
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Résumé
Octroi de licence obligatoire et capacité de production locale de médicaments en Afrique
L’Afrique porte le plus lourd fardeau de maladies dans le monde et 
continue de dépendre des importations de produits pharmaceutiques 
pour répondre à ses besoins de santé publique. Les fabricants asiatiques 
de médicaments génériques commencent à fonctionner sous un régime 
de propriété intellectuelle plus protectionniste; par conséquent, leur 
capacité de production de médicaments à des prix abordables pour les 
pays les plus pauvres est de plus en plus limitée. La Déclaration de Doha 
sur l’accord sur les ADPIC et la santé publique donne aux États membres 
de l’Organisation mondiale du commerce (OMC) le droit d’adopter une 
législation permettant l’utilisation de matériel breveté sans l’autorisation 
du détenteur du brevet, une disposition connue sous le nom « d’octroi 
de licence obligatoire ». Afin que les pays africains puissent profiter 
pleinement de l’octroi de licence obligatoire, ils doivent impérativement 
développer une importante capacité de production locale. Cependant, 
créer une capacité de production dans chaque pays africain est un 
défi presque impossible à relever; une zone de libre-échange en 
Afrique devrait donc être développée afin de servir de plateforme non 
seulement pour la libre-circulation des marchandises découlant des 
licences obligatoires, mais également pour instaurer une collaboration 
économique ou financière en vue de développer une forte capacité de 
production de produits pharmaceutiques sur le continent. La majorité 
des pays d’Afrique font partie de la liste des pays les moins avancés des 
Nations unies, ce qui leur permet, en vertu des dispositions de l’OMC, 
de refuser d’accorder des brevets pour les produits pharmaceutiques 
jusqu’en 2021. Par conséquent, les pays africains doivent impérativement 
collaborer pour créer maintenant une forte capacité de production 
pharmaceutique sur le continent, alors que les assouplissements du 
droit international de la propriété intellectuelle offrent encore des 
avantages considérables.
Резюме
Принудительное лицензирование патентов и местный потенциал производства лекарств в Африке
Африка со своим самым высоким бременем болезней в мире 
сохраняет зависимость от импорта лекарств для удовлетворения 
потребностей общественного здравоохранения. Поскольку 
азиатские производители лекарств-генериков начинают 
работать в рамках более жесткого протекционистского 
режима интеллектуальной собственности, их возможности 
производить лекарства по ценам, доступным для более бедных 
стран, становятся все более ограниченными. В принятой 
в Дохе Декларации о Соглашении ТРИПС и общественном 
здравоохранении государствам-членам Всемирной торговой 
организации (ВТО) предоставляется право принимать законы, 
разрешающее использование запатентованных материалов без 
разрешения патентообладателя. Этот положение также известно 
под названием «принудительное лицензирование». Чтобы 
африканские страны в полной мере смогли воспользоваться 
принудительным лицензированием, они должны обеспечить 
развитие значительных местных производственных мощностей. 
Хотя на строительство производственных мощностей в 
каждой африканской стране сложно рассчитывать, и эта 
перспектива совсем призрачна, необходимо развивать 
Африканскую зону свободной торговли, которая может 
послужить платформой не только для свободного перемещения 
товаров, изготовленных в соответствии с принудительными 
лицензиями, но и для экономического или финансового 
сотрудничества с целью создания мощного фармацевтического 
производства на континенте. Большинство стран Африки 
включены в список наименее развитых стран, составляемый 
Организацией Объединенных Наций, и это позволяет им в 
соответствии с законодательством ВТО отказывать в выдаче 
патентов на фармацевтические препараты до 2021 года. 
Таким образом, африканским странам непременно нужно 
развивать взаимноесотрудничество, чтобы создать сильную 
фармацевтическую промышленность на континенте уже 
сейчас, пока действующие нормы международного права 
интеллектуальной собственности еще предоставляют им 
значительные преимущества.
Resumen
La concesión obligatoria de licencias de patentes y la capacidad de fabricación local de medicamentos en África
África tiene la mayor carga de morbilidad del mundo y sigue 
dependiendo de las importaciones de productos farmacéuticos para 
cubrir las necesidades de salud pública. A medida que los fabricantes 
asiáticos de medicamentos genéricos comienzan a operar bajo un 
régimen de propiedad intelectual más proteccionista, su capacidad para 
producir medicamentos a precios que sean asequibles para los países 
más pobres es cada vez más limitada. La Declaración de Doha relativa al 
Acuerdo sobre los ADPIC y la Salud Pública ofrece a los Estados miembros 
de la Organización Mundial del Comercio (OMC) el derecho a adoptar la 
legislación que permite el uso de material patentado sin la autorización 
del titular de la patente, una disposición conocida como «licencia 
obligatoria». Los países africanos deben desarrollar una capacidad de 
producción local sustancial a fin de aprovechar al máximo las licencias 
obligatorias. Dado que aumentar la capacidad de producción en cada 
país africano resulta desalentador y casi irrealista, es necesario desarrollar 
una zona de libre comercio en África que sirva como una plataforma, 
no sólo para la libre circulación de mercancías de conformidad con las 
licencias obligatorias, sino también para establecer una colaboración 
económica o financiera encaminada a desarrollar una fuerte capacidad 
de fabricación de productos farmacéuticos en el continente. La mayoría 
de los países de África están en la lista de países menos desarrollados de 
las Naciones Unidas, por lo cual pueden, en virtud del derecho de la OMC, 
negarse a conceder patentes para productos farmacéuticos hasta 2021. 
Por tanto, existe una necesidad acuciante de que los países africanos 
colaboren ahora para desarrollar una fuerte capacidad de fabricación de 
productos farmacéuticos en el continente, mientras que las facilidades 
actuales del derecho internacional en materia de propiedad intelectual 
ofrecen beneficios notables. 
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